Reading CNS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CNS free→
CNS
Cohen & Steers, Inc.NYSEFinancialsAsset ManagementSnapshot 2026-06-12
Intact
$77.05+1.35%
Close 2026-06-12 · 1-day change
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
The bottom line
Recent financial performance is neutral, and earnings quality is fragile, reported profits aren't backed by cash. Management's recent track record has been fairly steady, and the company has a capital-friendly stance. Risk is moderate, and the sector backdrop is a headwind, which may impact performance compared to sector peers, where it is typical. Peer multiples imply a price about 74% below where it trades (it looks expensive on this basis); the read is rich, as it trades above peer multiples, and the longer horizon does not make that back through growth. If CNS cuts guidance on the next call, that could be a meaningful negative. This read is provisional.
as of 2026-06-12
Quick facts
- Exchange
- NYSE
- Sector
- Financials
- Industry
- Asset Management
- Market cap
- $3.91B
- Employees
- 424
- IPO date
- 2004-03-30
- Next earnings
- 2026-07-16
Price
Daily closes. Earnings/event dots are placed inline.
Adjusted daily closes (split & dividend). Scroll over the chart to zoom; click a range to reset.
EarningsMaterial event
What's priced in
(what the market already expects)What it's worth (estimated)
A consensus fair price across 7 valuation methods, at three horizons. Current price $77.05. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
12-month· primaryexpensive
$44.31consensus
Range $37.54 – $47.01
vs price: +74% above
Method agreement — · 7 methods
No-growth: today's peer multiple on trailing earnings. The headline read.
3-yearfull
$61.37consensus
Range $57.59 – $67.60
vs price: +26% above
Method agreement — · 6 methods
Embeds projected growth. Leans optimistic by design. Upside context.
5-yearfair
How much to trust our fair value
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
Durable premiumlow confidence
At $77 the market pays 25× p/e — above the 15× p/e peer median but in line with its own 24× history. That premium reflects a durable franchise our peer-anchored $44 fair value understates; treat the 'expensive vs peers' read with low confidence. Analysts: $75–$82. Not investment advice.
Multiple (P/E)
24.5x
peer 14.9x · own history 23.5x
Premium
1.6x peer
1.0x its own history
Growth the price needs
74%
our forecast 3%
Our fair value
$44.31
range $37.80 – $47.01
Analyst range(a guide on our number, not a target)Our number is below the analyst range
How this stock is priced
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Long-term · 1–3 yr
expensiverich12-month view
What's priced inUnjustified
The market is pricing in roughly 74% near-term growth, well above our forecast of about 3%. This describes what's priced in, not a forecast of the move.
High fragilityrisk posture, not a price call
Flags: expensive valuation, weak execution quality, a turbulent sector regime (Heating).
Historical context
For similar setups historically (n=889): about 49% saw a 20%+ drawdown, and roughly 85% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
How strong is the business
(quality & execution)Factor signals
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Recent financial performance
neutralOperating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Financials names rated neutral grew net income 52% of the time over the next year (vs 61% for the rest of the cohort, n=4936).
56th pctl · Financials
Earnings quality
fragileOver the trailing year it converted -0.40x of net income into operating cash flow. Historically, Financials names rated fragile grew net income 49% of the time over the next year (vs 60% for the rest of the cohort, n=3541).
5th pctl · Financials
Macro sensitivity
Most sensitive to the broad stock market.
- the broad stock market: This stock moves with the broad market (high beta).
Not enough signal to read sensitivity to real (inflation-adjusted) rates, long-term interest rates, the US dollar, Fed net liquidity.
Management & capital allocation
neutralEarnings setup & market context
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
Earnings setup · pre-print positioning
forward-looking
Strongly bullish2 analysts, 33% Buyfor period ending 2026-06-30
Why this setup
Consensus revisions
EPS estimate $0.82 → $0.83 (+1.2% / 30d). 1 raised, 0 cut, 2 covering analysts.
Rating actions
0 upgrades, 0 downgrades / 30d. 33% of analysts rate Buy.
Price target activity
1 PT revisions / 30d. Avg target 10.4% above current price.
Material events
1 positive, 0 negative / 30d. See F4 management tile for the event list.
Sector context
Intermediate · WeeklySector phase: is in (~3.2 years in phase).
Management scorecard
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Long-term · 1–3 yr
Overall: strong
- Capital allocation
- strong
- Earnings discipline
- strong
- Margin discipline
- strong
- Balance sheet
- neutral
- Post-call reaction
- strong
How bumpy is the path
(risk while you hold it)Risk: how this stock moves
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
Intermediate · WeeklyLong-term · 1–3 yr
On a typical day, $10k can swing ±$113.
How much price usually moves either way.
On a bad day, this stock has moved -$252.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $2,331.
Deepest peak-to-trough drop in the last year.
moderateas of 2026-06-12
Past results, not a forecast. Not investment advice.
What would change the read
(catalysts & re-read triggers)What changed
The most important moves since the prior daily snapshot.
Short-term · Daily
- No material changes since the prior snapshot.
No material changes since the prior snapshot.
as of 2026-06-12
What to watch next
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Intermediate · Weekly
- DownsideHigh confidenceQuartersactive 14d
Watch for Q2 revenue growth dropping below 1.3%
Why it matters: If revenue growth is low, it may show problems ahead. Investors pay close attention to revenue.
What confirms / what disproves
Confirms:Q2 revenue growth reported below 1.3% year over year.
Disproves:Q2 revenue growth reported above 1.3% year over year.
Sector context
News catalysts
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for CNS yet.
This sector is also watching
- Watch for revenue growth dropping below 10% across major banks
- Watch for changes in FOMC interest rate policy on June 17
What could change this view
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Intermediate · Weekly
Upside triggers
- If sector bellwethers like BLK, BX, and KKR keep beating earnings and guiding higher, the Financials sector momentum should keep lifting CNS and other Financials names. Worth watching these names for early signals.
- If CNS raises forward guidance on the next earnings call (currently NEW as of 2026-01-22), that's a momentum boost. Street estimates typically follow guidance up and the stock tends to re-rate higher.
Downside triggers
- If CNS cuts guidance on the next call (currently NEW as of 2026-01-22), that's a meaningful negative. The Street tends to walk down estimates and the stock usually takes a leg lower.
- If the Fed starts cutting rates from the current 3.62%, that would weigh on CNS and other Financials names, since the sector usually outperforms when rates stay high.
- If sector bellwethers like BLK, BX, and KKR start missing or guiding lower, the Financials tailwind helping CNS and other Financials names could fade. Watch these names for early warning.
Recent events
(material 8-K / filing activity)Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-05-2123d agoItem 5.02
Chief Financial Officer — Amit Muni: The company hired a new CFO from an external source.
Executive changepositive
Score history
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
+9.4 vs last weeklatest as of 2026-06-13
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.